Cargando…

Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy

The interaction of immune checkpoint molecules in the tumor microenvironment reduces the anti-tumor immune response by suppressing the recognition of T cells to tumor cells. Immune checkpoint inhibitor (ICI) therapy is emerging as a promising therapeutic option for cancer treatment. However, modulat...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Juwon, Han, Youngjin, Wang, Wenyu, Jo, HyunA, Kim, Heeyeon, Kim, Soochi, Yang, Kyung-Min, Kim, Seong-Jin, Dhanasekaran, Danny N., Song, Yong Sang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393583/
https://www.ncbi.nlm.nih.gov/pubmed/34439774
http://dx.doi.org/10.3390/biom11081107
_version_ 1783743758420934656
author Lee, Juwon
Han, Youngjin
Wang, Wenyu
Jo, HyunA
Kim, Heeyeon
Kim, Soochi
Yang, Kyung-Min
Kim, Seong-Jin
Dhanasekaran, Danny N.
Song, Yong Sang
author_facet Lee, Juwon
Han, Youngjin
Wang, Wenyu
Jo, HyunA
Kim, Heeyeon
Kim, Soochi
Yang, Kyung-Min
Kim, Seong-Jin
Dhanasekaran, Danny N.
Song, Yong Sang
author_sort Lee, Juwon
collection PubMed
description The interaction of immune checkpoint molecules in the tumor microenvironment reduces the anti-tumor immune response by suppressing the recognition of T cells to tumor cells. Immune checkpoint inhibitor (ICI) therapy is emerging as a promising therapeutic option for cancer treatment. However, modulating the immune system with ICIs still faces obstacles with severe immunogenic side effects and a lack of response against many cancer types. Plant-derived natural compounds offer regulation on various signaling cascades and have been applied for the treatment of multiple diseases, including cancer. Accumulated evidence provides the possibility of efficacy of phytochemicals in combinational with other therapeutic agents of ICIs, effectively modulating immune checkpoint-related signaling molecules. Recently, several phytochemicals have been reported to show the modulatory effects of immune checkpoints in various cancers in in vivo or in vitro models. This review summarizes druggable immune checkpoints and their regulatory factors. In addition, phytochemicals that are capable of suppressing PD-1/PD-L1 binding, the best-studied target of ICI therapy, were comprehensively summarized and classified according to chemical structure subgroups. It may help extend further research on phytochemicals as candidates of combinational adjuvants. Future clinical trials may validate the synergetic effects of preclinically investigated phytochemicals with ICI therapy.
format Online
Article
Text
id pubmed-8393583
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83935832021-08-28 Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy Lee, Juwon Han, Youngjin Wang, Wenyu Jo, HyunA Kim, Heeyeon Kim, Soochi Yang, Kyung-Min Kim, Seong-Jin Dhanasekaran, Danny N. Song, Yong Sang Biomolecules Review The interaction of immune checkpoint molecules in the tumor microenvironment reduces the anti-tumor immune response by suppressing the recognition of T cells to tumor cells. Immune checkpoint inhibitor (ICI) therapy is emerging as a promising therapeutic option for cancer treatment. However, modulating the immune system with ICIs still faces obstacles with severe immunogenic side effects and a lack of response against many cancer types. Plant-derived natural compounds offer regulation on various signaling cascades and have been applied for the treatment of multiple diseases, including cancer. Accumulated evidence provides the possibility of efficacy of phytochemicals in combinational with other therapeutic agents of ICIs, effectively modulating immune checkpoint-related signaling molecules. Recently, several phytochemicals have been reported to show the modulatory effects of immune checkpoints in various cancers in in vivo or in vitro models. This review summarizes druggable immune checkpoints and their regulatory factors. In addition, phytochemicals that are capable of suppressing PD-1/PD-L1 binding, the best-studied target of ICI therapy, were comprehensively summarized and classified according to chemical structure subgroups. It may help extend further research on phytochemicals as candidates of combinational adjuvants. Future clinical trials may validate the synergetic effects of preclinically investigated phytochemicals with ICI therapy. MDPI 2021-07-27 /pmc/articles/PMC8393583/ /pubmed/34439774 http://dx.doi.org/10.3390/biom11081107 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Lee, Juwon
Han, Youngjin
Wang, Wenyu
Jo, HyunA
Kim, Heeyeon
Kim, Soochi
Yang, Kyung-Min
Kim, Seong-Jin
Dhanasekaran, Danny N.
Song, Yong Sang
Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy
title Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy
title_full Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy
title_fullStr Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy
title_full_unstemmed Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy
title_short Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy
title_sort phytochemicals in cancer immune checkpoint inhibitor therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393583/
https://www.ncbi.nlm.nih.gov/pubmed/34439774
http://dx.doi.org/10.3390/biom11081107
work_keys_str_mv AT leejuwon phytochemicalsincancerimmunecheckpointinhibitortherapy
AT hanyoungjin phytochemicalsincancerimmunecheckpointinhibitortherapy
AT wangwenyu phytochemicalsincancerimmunecheckpointinhibitortherapy
AT johyuna phytochemicalsincancerimmunecheckpointinhibitortherapy
AT kimheeyeon phytochemicalsincancerimmunecheckpointinhibitortherapy
AT kimsoochi phytochemicalsincancerimmunecheckpointinhibitortherapy
AT yangkyungmin phytochemicalsincancerimmunecheckpointinhibitortherapy
AT kimseongjin phytochemicalsincancerimmunecheckpointinhibitortherapy
AT dhanasekarandannyn phytochemicalsincancerimmunecheckpointinhibitortherapy
AT songyongsang phytochemicalsincancerimmunecheckpointinhibitortherapy